Asthma is not one disease but a spectrum of chronic airway inflammation affecting over 260 million people worldwide. Its hallmark is airway hyperresponsiveness — the tendency of the airways to narrow excessively in response to triggers that would barely affect a healthy lung. For most patients inhaled corticosteroids and bronchodilators provide adequate control, but an estimated 5–10% live with severe, treatment-resistant disease. These patients cycle through exacerbations, oral steroid bursts, and progressive loss of lung function despite maximal therapy. It is in this gap that mesenchymal stem cell research has begun to attract serious scientific attention — not as a replacement for inhalers, but as a potential disease-modifying strategy that targets the underlying immune dysregulation.[1][2]

What Goes Wrong in the Asthmatic Airway

At its core, asthma is an immunological disorder of the conducting airways. In the most common phenotype — allergic or type-2-high asthma — the immune system mounts an exaggerated Th2 response to otherwise innocuous environmental proteins. Dendritic cells present allergens to naive T cells, driving their differentiation into Th2 lymphocytes that secrete interleukin-4 (IL-4), IL-5, and IL-13. IL-5 mobilises eosinophils from the bone marrow and sustains their survival in tissue. IL-4 and IL-13 promote IgE class-switching in B cells, sensitising mast cells for degranulation on re-exposure. The result is a self-perpetuating cycle: eosinophilic infiltration, mast-cell activation, mucus hypersecretion, and bronchial smooth-muscle constriction.[3][4]

Over years, the inflammatory milieu remodels the airway wall. Subepithelial collagen deposition thickens the basement membrane. Smooth muscle hypertrophies and hyperplasias. Goblet cells proliferate, pouring excess mucus into an already-narrowed lumen. This structural remodelling is what makes severe asthma progressive — each exacerbation accelerates the process, and the thickened, stiffened airway responds less and less to bronchodilators. Conventional therapies manage symptoms and dampen inflammation, but none reverse established remodelling or reset the underlying immune polarity.[5]

How MSC Therapy Targets the Immune Drivers of Asthma

Mesenchymal stem cells possess a unique immunomodulatory repertoire that directly addresses the Th2-driven pathology of asthma. MSCs do not engraft as structural lung cells; their therapeutic effect is paracrine and contact-dependent — they sense the inflammatory milieu and respond by secreting a cocktail of bioactive molecules that recalibrate the immune response. In the context of allergic airway disease, this means shifting the balance away from destructive Th2 dominance and toward regulatory tolerance.[6][7]

Several mechanisms have been demonstrated in preclinical models. MSCs suppress Th2 proliferation and cytokine production (IL-4, IL-5, IL-13) while simultaneously expanding regulatory T cells — the Treg population that normally keeps allergic responses in check. They promote a shift from the pro-allergic Th2 phenotype toward a Th1/Th2 balance, partly through prostaglandin E2 (PGE2) and indoleamine 2,3-dioxygenase (IDO) pathways. MSCs also directly inhibit eosinophil survival and activation, reduce mast-cell degranulation, and downregulate dendritic-cell maturation — effectively intervening at multiple nodes of the allergic cascade.[8][9]

The anti-fibrotic potential is equally relevant. MSC-derived factors including hepatocyte growth factor (HGF) and transforming growth factor-beta (TGF-β) modulation have been shown to attenuate subepithelial fibrosis and smooth-muscle hyperplasia in animal models of chronic asthma. By suppressing the transforming growth factor-beta / Smad signalling axis that drives collagen deposition, MSCs may slow or partially reverse the airway remodelling that makes severe asthma progressive. This is early preclinical work, but it hints at a disease-modifying mechanism that no current inhaler can offer.[10]

MSC immunomodulation visualization — mesenchymal stem cells releasing anti-inflammatory cytokines to suppress Th2-driven airway inflammation
MSCs intervene at multiple points in the allergic cascade: suppressing Th2 cytokines, expanding regulatory T cells, inhibiting eosinophil survival, and attenuating mast-cell degranulation — a breadth of action that distinguishes them from single-cytokine biologics.

What the Clinical Evidence Shows

The clinical data for MSC therapy in asthma remain early-phase but biologically encouraging. Most published studies are Phase I safety and feasibility trials enrolling small numbers of patients with severe, refractory disease. The consistent headline across these studies is that intravenous infusion of allogeneic MSCs — typically umbilical-cord-derived or bone-marrow-derived — has been well tolerated, with no serious adverse events attributable to the cells themselves. Infusional reactions are uncommon and mild when they occur. This safety record, now replicated across several independent centres, is the foundation on which larger efficacy trials are being built.[11]

Signal-finding is more tentative but directionally consistent. A 2022 first-in-human study of umbilical-cord-derived MSCs in severe asthma reported reductions in peripheral blood eosinophil counts and improvements in asthma control questionnaire (ACQ) scores at 12 months in several patients — while noting the absence of a placebo control and small sample size. Other Phase I protocols have reported decreased rescue-inhaler use and trends toward improved FEV1, though none has yet reached statistical significance in a randomised, placebo-controlled design. These are signals, not proof — the kind of data that justifies larger trials but does not yet support conclusions about efficacy.[12]

Important: As of today, no regulatory body has approved MSC therapy as a treatment for asthma. All published human data come from early-phase clinical trials. Any clinic presenting MSC therapy as a proven asthma treatment is making claims that outrun the evidence. Responsible providers describe this as an investigational approach with encouraging preclinical rationale and preliminary safety data.

Comparing MSC Therapy with Conventional Asthma Treatments

Current asthma management follows a stepwise escalation from inhaled corticosteroids and short-acting beta-agonists through long-acting bronchodilators, leukotriene modifiers, and, for severe disease, biologic agents targeting specific cytokines (anti-IgE omalizumab, anti-IL-5 mepolizumab/reslizumab, anti-IL-4Rα dupilumab, anti-TSLP tezepelumab). Biologics have transformed severe asthma care, but they target single pathways and are effective only in biomarker-defined subpopulations. They also require ongoing administration — they control disease rather than modify its trajectory.[13]

MSC therapy differs conceptually from both small-molecule and biologic approaches. Rather than blocking one cytokine or receptor, MSCs deliver a broad-spectrum immunomodulatory signal that simultaneously suppresses multiple Th2 effector pathways while promoting regulatory tolerance. This breadth of action — what some researchers call "polyclonal immunomodulation" — is both the promise and the challenge. It means MSCs could theoretically benefit patients across asthma phenotypes without biomarker preselection. But it also makes the mechanism harder to pin down and the dose-response relationship harder to characterise. A well-designed biologic has a clean pharmacodynamic curve; MSCs work through a network of paracrine signals whose net effect depends on the host environment.

What to Expect: Procedure and Potential Timeline

In the clinical trial setting, MSC administration for asthma is most commonly intravenous. Cells are thawed at the bedside from cryopreserved aliquots, suspended in saline, and infused over 30–60 minutes with standard vital-sign monitoring. Some protocols use a single infusion; others administer multiple doses spaced weeks or months apart, based on the hypothesis that repeated dosing may sustain immunomodulatory pressure on the chronic inflammatory milieu. The procedure is outpatient-based and does not require sedation or bronchoscopic delivery — a practical advantage for a condition that primarily affects the conducting airways.

Timeline expectations should be conservative. Unlike bronchodilators, which work in minutes, MSC therapy — if it works — is expected to produce gradual, cumulative improvement over weeks to months. Preclinical data and early human signals suggest that changes in inflammatory markers (eosinophil counts, exhaled nitric oxide) may be detectable within 4–8 weeks, while clinical outcomes such as ACQ scores, exacerbation frequency, and spirometry would require 3–12 months of follow-up to assess meaningfully. This is not a rescue therapy; it is being studied as a disease-modifying intervention.

Risks, Limitations, and What We Still Don't Know

The safety record is reassuring but incomplete. Across published Phase I trials in asthma and the larger MSC safety literature in other conditions (COPD, ARDS, graft-versus-host disease), intravenous allogeneic MSCs have shown low rates of acute infusional reactions and no evidence of tumour formation or ectopic tissue growth. Longer-term safety data — beyond 2–5 years — are sparse simply because the field is young. Theoretical concerns include immunogenicity with repeated allogeneic dosing (though MSCs are considered immune-privileged, anti-donor antibodies have been detected in some protocols) and the possibility that MSCs could, in certain microenvironments, promote rather than suppress fibrosis. These remain hypothetical but underscore why Phase III trials with long follow-up are essential.[14]

What we still don't know is substantial. The optimal cell source (umbilical cord versus bone marrow versus adipose), dose, and dosing interval for asthma have not been defined. It is unclear whether certain asthma phenotypes (allergic versus non-allergic, type-2-high versus type-2-low) respond differently. The durability of any benefit — whether a course of MSC therapy could induce long-term immune tolerance or would require periodic re-dosing — is entirely unstudied. And the absence of standardised potency assays means MSC products from different manufacturers may differ in biological activity even when cell counts match. These are not minor gaps; they are the questions that separate an investigational therapy from an established one.

Frequently Asked Questions

Can stem cell therapy cure asthma?

No. No cell therapy has been shown to cure asthma, and claims of a "cure" are not supported by evidence. MSC therapy is being studied as a potential disease-modifying intervention that may reduce airway inflammation, decrease exacerbation frequency, and improve symptom control — but it is not curative. Responsible researchers describe the goal as long-term disease modification, not cure.

How much does stem cell therapy for asthma cost in Thailand?

Costs vary by clinic, cell source, and protocol, but a single intravenous MSC infusion in Thailand typically ranges from USD 8,000 to USD 15,000. Multiple-infusion protocols cost proportionally more. Because this is an investigational therapy, it is generally not covered by insurance. Patients should request a detailed breakdown of what the fee includes — cell characterisation data, sterility certification, follow-up monitoring — before committing.

Is MSC therapy safe for people with severe asthma?

Early-phase clinical trials have reported that intravenous MSC infusion is well tolerated in patients with severe asthma, with no serious cell-related adverse events. However, the total number of treated patients remains small (fewer than 200 across all published protocols), so rare risks cannot be excluded. Patients with severe asthma should discuss any investigational therapy with their treating pulmonologist and should prioritise enrolment in registered clinical trials where safety monitoring is standardised.

How is MSC therapy different from biologic injections like omalizumab or dupilumab?

Biologics target a single cytokine or receptor (IgE, IL-5, IL-4Rα, TSLP) and are effective only in patients whose asthma is driven by that specific pathway. MSCs deliver a broad-spectrum immunomodulatory signal that simultaneously affects multiple Th2 effector pathways while promoting regulatory tolerance. This means MSCs could theoretically work across asthma phenotypes, but the evidence is far less mature — biologics are supported by large Phase III trials and real-world registries; MSCs are not.

Will I still need my inhalers after MSC therapy?

Yes. MSC therapy is being studied as an adjunct to — not a replacement for — standard asthma pharmacotherapy. In clinical trials, patients continue their prescribed controller medications throughout the study period. No trial has suggested that MSC therapy eliminates the need for maintenance therapy, and abruptly discontinuing inhaled corticosteroids can trigger life-threatening exacerbations.

A Responsible Perspective

Asthma research has produced genuinely transformative therapies — inhaled steroids, combination inhalers, and, more recently, biologics — and patients today have far better options than a generation ago. MSC therapy enters this landscape not as a competitor to proven treatments but as a candidate for the unmet need that remains: severe, treatment-resistant disease that progresses despite maximal conventional therapy. The preclinical rationale is strong, the early safety data are reassuring, and the immunological mechanisms align well with the pathophysiology of type-2-high asthma. What is missing is efficacy data from adequately powered, randomised, placebo-controlled Phase III trials — and that gap is the difference between an investigational approach and a treatment.

At VELAR Center, we follow respiratory MSC research with great interest and apply it only in contexts supported by a meaningful body of evidence. For asthma, that means having honest conversations about where the science stands — promising but still early — rather than making claims the data cannot yet support. If you are considering regenerative options for severe asthma, the single most important question you can ask any provider is: What published, peer-reviewed evidence supports the specific protocol you are recommending? A trustworthy answer will acknowledge the investigational nature of the field and the limits of current knowledge.

References

  1. GBD 2019 Asthma Collaborators. Global, regional, and national burden of asthma and its risk factors from 1990 to 2019: a systematic analysis. The Lancet Respiratory Medicine. 2023;11(5):426-441. doi:10.1016/S2213-2600(22)00525-2 ↩
  2. Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. The Lancet. 2023;401(10379):858-873. doi:10.1016/S0140-6736(22)02125-0 ↩
  3. Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50(4):975-991. doi:10.1016/j.immuni.2019.03.018 ↩
  4. Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184(6):1469-1485. doi:10.1016/j.cell.2021.02.016 ↩
  5. Fehrenbach H, Wagner C, Wegmann M. Airway remodeling in asthma: what really matters. Cell and Tissue Research. 2017;367(3):551-569. doi:10.1007/s00441-016-2566-8 ↩
  6. Gao F, Chiu SM, Motan DA, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death & Disease. 2016;7(1):e2062. doi:10.1038/cddis.2015.327 ↩
  7. Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. Journal of Immunology Research. 2015;2015:394917. doi:10.1155/2015/394917 ↩
  8. Abreu SC, Weiss DJ, Rocco PRM. Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases? Stem Cell Research & Therapy. 2016;7(1):53. doi:10.1186/s13287-016-0317-0 ↩
  9. Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy. 2011;66(4):523-531. doi:10.1111/j.1398-9995.2010.02509.x ↩
  10. Firinci F, Karaman M, Baran Y, et al. Mesenchymal stem cells ameliorate the histopathological changes in a murine model of chronic asthma. International Immunopharmacology. 2011;11(8):1120-1126. doi:10.1016/j.intimp.2011.03.009 ↩
  11. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  12. Mathias LJ, Khong SML, Spyroglou L, et al. Autologous mesenchymal stromal cells for chronic severe asthma: a phase I first-in-human study. Cytotherapy. 2022;24(5):S29-S30. doi:10.1016/j.jcyt.2022.01.047 ↩
  13. Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. New England Journal of Medicine. 2022;386(2):157-171. doi:10.1056/NEJMra2032506 ↩
  14. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩
  15. Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung diseases. Expert Review of Respiratory Medicine. 2020;14(1):31-39. doi:10.1080/17476348.2020.1679628 ↩
  16. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩